Dent for Bayer blockbuster hopes for vilaprisan

6 December 2018

German group Bayer (BAYN: DE) is halting trials of its uterine fibroids candidate, vilaprisan.

Toxicology findings from long-term tests that were going on in rodents alongside the human trials have caused enough concern for Bayer to stop enrolment and evaluate the data gathered so far as a precautionary measure, drug development head Joerg Moeller said during Wednesday’s capital markets day in London.

Bayer had launched a Phase III trial of vilaprisan in July of last year, and had previously predicted sales for the drug exceeding $1.1 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK